We are moving to new facilities to meet rapidly growing demand for products and services
We are pleased to announce that The Native Antigen Company is moving to new, expanded bespoke facilities with effect from April 27th. 2017
These new facilities will enable us to meet the rapidly increasing demand for our products and services and will also allow our ground-breaking R&D scientists to continue working on new developments to further support the needs of our growing customer base.
Contract protein production and assay development services
In addition to our world-leading range of antigens for infectious disease assay development, vaccine studies and R&D applications, we can now offer expanded capacity for contract recombinant protein production in our mammalian expression system, together with immunoassay development services. This includes both ELISA and lateral flow devices.